Nothing Special   »   [go: up one dir, main page]

ATE300541T1 - Pyrazolopyridinderivate - Google Patents

Pyrazolopyridinderivate

Info

Publication number
ATE300541T1
ATE300541T1 AT01987099T AT01987099T ATE300541T1 AT E300541 T1 ATE300541 T1 AT E300541T1 AT 01987099 T AT01987099 T AT 01987099T AT 01987099 T AT01987099 T AT 01987099T AT E300541 T1 ATE300541 T1 AT E300541T1
Authority
AT
Austria
Prior art keywords
pyrazolopyridine derivatives
same
pyrazolopyridine
derivatives
variables
Prior art date
Application number
AT01987099T
Other languages
English (en)
Inventor
F Leslie Boyd
Stanley D Chamberlain
Mui Cheung
Kristjan Gudmundsson
Philip Anthony Harris
Brian A Johns
David Kendall Jung
Michael Robert Peel
Jennifer G Stanford
Connie Jo Sexton
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE300541T1 publication Critical patent/ATE300541T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT01987099T 2000-12-15 2001-11-26 Pyrazolopyridinderivate ATE300541T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25576300P 2000-12-15 2000-12-15
US27428401P 2001-03-08 2001-03-08
PCT/US2001/044231 WO2002048148A2 (en) 2000-12-15 2001-11-26 Pyrazolopyridine derivatives

Publications (1)

Publication Number Publication Date
ATE300541T1 true ATE300541T1 (de) 2005-08-15

Family

ID=26944940

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01987099T ATE300541T1 (de) 2000-12-15 2001-11-26 Pyrazolopyridinderivate

Country Status (8)

Country Link
US (2) US7163940B2 (de)
EP (1) EP1377573B1 (de)
JP (1) JP2004515550A (de)
AT (1) ATE300541T1 (de)
AU (1) AU2002239348A1 (de)
DE (1) DE60112330T2 (de)
ES (1) ES2243579T3 (de)
WO (1) WO2002048148A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1377573B1 (de) 2000-12-15 2005-07-27 Glaxo Group Limited Pyrazolopyridinderivate
EP1341788B1 (de) 2000-12-15 2005-08-10 Glaxo Group Limited Pyrazolopyridine
WO2002072581A2 (en) 2001-03-08 2002-09-19 Smithkline Beecham Corporation Pyrazolopyriadine derivatives
JP4237497B2 (ja) 2001-03-30 2009-03-11 スミスクライン ビーチャム コーポレーション ピラゾロピリジン類、その調製方法及びその治療用化合物としての使用
EP1372642A1 (de) * 2001-03-30 2004-01-02 SmithKline Beecham Corporation Verwendung von pyrazolopyridinen als therapeutika
EP1377575B1 (de) 2001-04-10 2006-07-05 SmithKline Beecham Corporation Antivirale pyrazolopyridin verbindungen
US6962914B2 (en) 2001-04-27 2005-11-08 Smithkline Beecham Corporation Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds
ES2271273T3 (es) 2001-06-21 2007-04-16 Smithkline Beecham Corporation Derivados imidazo-1,2-aipiridina para la profilaxis y tratamiento de las infecciones del virus del herpres.
US7115617B2 (en) 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
WO2003022845A1 (en) * 2001-09-07 2003-03-20 Smithkline Beecham Corporation Pyrazolo-pyridines for the treatment of herpes infections
ATE326466T1 (de) 2001-10-05 2006-06-15 Smithkline Beecham Corp Imidazopyridinderivate zur verwendung bei der behandlung von herpes-vireninfektion
ATE373000T1 (de) 2001-12-11 2007-09-15 Smithkline Beecham Corp Pyrazolopyridin-derivate als antiherpesmittel
JP2005525382A (ja) 2002-03-07 2005-08-25 スミスクライン ビーチャム コーポレーション ピラゾロピリミジンおよびピラゾロトリアジン誘導体ならびにそれを含む医薬組成物
JP2006504728A (ja) * 2002-10-03 2006-02-09 スミスクライン ビーチャム コーポレーション ピラソロピリジン誘導体系治療用化合物
EP1644338A1 (de) * 2003-04-01 2006-04-12 Aponetics AG 2,4,6-trisubstituierte pyrimidinderivate, die sich für die behandlung von neoplastischen krankheiten und autoimmunkrankheiten eignen
WO2006055245A2 (en) * 2004-11-17 2006-05-26 Smithkline Beecham Corporation Process for preparing pyrazolopyridine compounds
CN101223146A (zh) 2005-05-24 2008-07-16 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的调控剂
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
EP2536410B1 (de) * 2010-02-18 2015-09-23 Merck Sharp & Dohme Corp. Substituierte pyrimidinderivate und ihre verwendung bei der behandlung viraler infektionen
EP2402335A1 (de) 2010-06-29 2012-01-04 Basf Se Pyrazolopyridin-Verbindungen
EP2402336A1 (de) 2010-06-29 2012-01-04 Basf Se Pyrazolopyridin-Verbindungen
CN103958518B (zh) * 2011-10-06 2017-07-04 拜耳知识产权有限责任公司 杂环基吡啶基吡唑/杂环基嘧啶基吡唑
SG10201600149VA (en) 2012-11-21 2016-02-26 Ptc Therapeutics Inc Substituted reverse pyrimidine bmi-1 inhibitors
JP2021535198A (ja) 2018-08-17 2021-12-16 ピーティーシー セラピューティクス, インコーポレイテッド 膵臓癌を治療する方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US46478A (en) * 1865-02-21 Isaac s
US3666440A (en) * 1970-03-13 1972-05-30 Mitsubishi Metal Mining Co Ltd Method of recovering copper from slag
EP0151962A3 (de) 1984-01-25 1985-10-02 Beecham Group Plc Pyrazolopyridin-Derivate
GB8404584D0 (en) 1984-02-22 1984-03-28 Beecham Group Plc Compounds
GB8404586D0 (en) 1984-02-22 1984-03-28 Beecham Group Plc Compounds
US5002941A (en) 1985-12-12 1991-03-26 Smithkline Beecham Corporation Pyrrolo(1,2-a)imidazole and imidazo(1,2-a)pyridine derivatives and their use as 5-lipoxygenase pathway inhibitors
US4925849A (en) 1987-06-15 1990-05-15 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutically useful pyrazolopyridines
US5155114A (en) 1989-01-23 1992-10-13 Fujisawa Pharmaceutical Company, Ltd. Method of treatment using pyrazolopyridine compound
GB8901423D0 (en) 1989-01-23 1989-03-15 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
WO1991000092A1 (en) 1989-06-13 1991-01-10 Smithkline Beecham Corporation Inhibition of interleukin-1 and tumor necrosis factor production by monocytes and/or macrophages
AU622330B2 (en) 1989-06-23 1992-04-02 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds having a nitrogen atom in the bridgehead for use as fungicides
JPH05508153A (ja) 1990-06-12 1993-11-18 スミスクライン・ビーチャム・コーポレイション 5―リポキシゲナーゼ経路およびシクロオキシゲナーゼ経路で媒介される疾患の阻害
GB9015764D0 (en) 1990-07-18 1990-09-05 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
CA2060138A1 (en) 1991-01-29 1992-07-30 Youichi Shiokawa New use of the adenosine antagonist
GB9107513D0 (en) 1991-04-10 1991-05-29 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
US5300478A (en) 1993-01-28 1994-04-05 Zeneca Limited Substituted fused pyrazolo compounds
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5552422A (en) 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
TR199701105T1 (xx) 1995-04-04 1998-02-21 Glaxo Group Limited �midazo (1,2-a)piridin t�revleri.
EP0833664A1 (de) 1995-06-12 1998-04-08 G.D. SEARLE & CO. Kombination aus einem cyclooxygenase-2 inhibitor und einem leukotrien b4 rezeptorantagonisten zur behandlung von entzündungen
ES2247604T3 (es) 1995-06-12 2006-03-01 G.D. SEARLE & CO. Composiciones que comprenden un inhibidor de ciclooxigenasa-2 y un inhibidor de 5-lipoxigenasa.
US5700816A (en) 1995-06-12 1997-12-23 Isakson; Peter C. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
FR2757059B1 (fr) 1996-12-12 1999-01-29 Rhone Poulenc Rorer Sa Nouvelle application therapeutique des derives du pyrrole
FR2757166B1 (fr) 1996-12-12 1999-01-29 Rhone Poulenc Rorer Sa Derives du pyrrole, leur preparation et les compositions pharmaceutiques qui les contiennent
EP1023066A4 (de) 1997-06-13 2001-05-23 Smithkline Beecham Corp Neue pyrazole- und pyrazoline- substituierte verbindung
EP1510519B1 (de) 1997-09-05 2006-02-15 Glaxo Group Limited Pharmazeutische Zusammensetzung, enthaltend 2,3-Diaryl-Pyrazolo[1,5-b]Pyridazin Derivate
WO1999058523A1 (en) 1998-05-14 1999-11-18 G.D. Searle & Co. 1,5-DIARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS
US6245789B1 (en) 1998-05-19 2001-06-12 The Procter & Gamble Company HIV and viral treatment
FR2779724B1 (fr) 1998-06-10 2001-04-20 Rhone Poulenc Rorer Sa Derives du pyrrole, leur preparation et les compositions pharmaceutiques qui les contiennent
HUP0104204A3 (en) 1998-11-03 2002-06-28 Glaxo Group Ltd Pyrazolopyridine derivatives as cox-2 inhibitors, process for their preparation and pharmaceutical compositions thereof
ATE261444T1 (de) 1999-02-27 2004-03-15 Glaxo Group Ltd Pyrazolopyridine
IL147328A0 (en) 1999-06-28 2002-08-14 Janssen Pharmaceutica Nv Respiratory syncytial virus replication inhibitors
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
AUPQ969800A0 (en) 2000-08-28 2000-09-21 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
EP1377573B1 (de) 2000-12-15 2005-07-27 Glaxo Group Limited Pyrazolopyridinderivate
EP1341788B1 (de) 2000-12-15 2005-08-10 Glaxo Group Limited Pyrazolopyridine
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
EP1372642A1 (de) * 2001-03-30 2004-01-02 SmithKline Beecham Corporation Verwendung von pyrazolopyridinen als therapeutika
US6962914B2 (en) * 2001-04-27 2005-11-08 Smithkline Beecham Corporation Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds
CA2450555A1 (en) 2001-06-25 2003-01-03 Merck & Co., Inc. (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds
BR0317140B1 (pt) * 2002-12-12 2013-07-30 " mÉtodo para projetar uma montagem de ferramenta de furo de sondagem "

Also Published As

Publication number Publication date
DE60112330T2 (de) 2006-04-13
ES2243579T3 (es) 2005-12-01
EP1377573B1 (de) 2005-07-27
AU2002239348A1 (en) 2002-06-24
DE60112330D1 (en) 2005-09-01
JP2004515550A (ja) 2004-05-27
EP1377573A2 (de) 2004-01-07
US7163940B2 (en) 2007-01-16
WO2002048148A3 (en) 2003-05-01
US20070287721A1 (en) 2007-12-13
US20050049259A1 (en) 2005-03-03
WO2002048148A2 (en) 2002-06-20

Similar Documents

Publication Publication Date Title
ATE301653T1 (de) Pyrazolopyridine
ATE296826T1 (de) Pyrazolo(1,5)pyridinderivate
ATE300541T1 (de) Pyrazolopyridinderivate
ATE433447T1 (de) Pyrimiidinverbindungen
DE60212949D1 (de) Antivirale pyrazolopyridin verbindungen
AU2003228770A8 (en) Substituted pyrazolopyrimidines
IS6658A (is) Ný efnasambönd
DE60214179D1 (de) IMIDAZOi1,2-AöPYRIDIN-DERIVATE ZUR PROPHYLAXE UND BEHANDLUNG VON HERPES-INFEKTIONEN
NO20050525L (no) Benzimidazol-1-yl-tiofenforbindelser for behandling av cancer
PT1263724E (pt) Novos compostos
ATE364043T1 (de) Pyrazolo-pyridine für die behandlung von herpes- ansteckungen
MXPA05012247A (es) Derivados de bencimidazol nuevos.
DE60211539D1 (de) Imidazopyridinderivate zur verwendung bei der behandlung von herpes-vireninfektion
SE0302139D0 (sv) Novel compounds
ATE302203T1 (de) Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen
SE9804212D0 (sv) Compounds
ATE274515T1 (de) Pyrazolopyridinderivate
ATE373000T1 (de) Pyrazolopyridin-derivate als antiherpesmittel
SE9904128D0 (sv) Novel compounds
ATE315038T1 (de) Antibakterielle mittel
SE0004480D0 (sv) Novel compounds
SE0002330D0 (sv) Novel compounds

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties